Keryx Biopharmaceuticals Jumps on Kidney Drug Results
January 28, 2013 - 2:54pm
The stock price of Keryx Biopharmaceuticals (NASDAQ:KERX) jumped by more than 90 percent to around $6.50 a share as of this writing after the company announced the successful results from the long-term Phase 3 study of its experimental drug, ZerenexThe post Keryx Biopharmaceuticals Jumps on Kidney Drug Results appeared first on ValueWalk.
Continue reading this article »
Share This Article: